Cost-effectiveness of rHu-EPO in oncology

  • Pierre-Y. Cremieux
  • E. Dial
  • M. Gustafson
  • B. Sarokhan
  • M. B. Slavin


Approximately 13 million Americans are diagnosed with cancer every year and the various therapies they receive are often as physically trying as the cancer itself [2, 26]. Pain, nausea, infection, and anemia are common and debilitating side effects experienced by many patients undergoing chemotherapy and radiotherapy. As attention has turned toward improving the quality of life for patients undergoing treatment, many advances have been made in managing these side effects [14, 27, 33]. However, a treatment for anemia beyond traditional blood transfusions remained elusive until the introduction of recombinant human erythropoietin “rHu-EPO (epoetin alfa)”, which made it possible to aggressively treat anemia [10, 13, 14, 18, 22–24, 31].


Recombinant Human Erythropoietin Excess Cost Lost Productivity High Hemoglobin Level Indirect Medical Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (Supp12): S2 — S8CrossRefGoogle Scholar
  2. 2.
    American Cancer Society. Statistics: How many new cases are expected to occur this year? Available at: asp ?ct=1 &ctid =8&scp= &pnt=2&language=english. Accessed January 11, 2001Google Scholar
  3. 3.
    Barnett A, Birnbaum HG, Cremieux PY, Fendrick AM, Slavin M (2000) The cost of cancer to a major employer in the United States: a case control analysis. Am J Managed Care 11 (6): 1243–1251Google Scholar
  4. 4.
    Cost-effectiveness of rHu-EPO in oncology 445Google Scholar
  5. Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia. Br J Cancer 78 (6): 781–787PubMedCrossRefGoogle Scholar
  6. 5.
    Blajchman MA (1998) Immunomodulatory effects of allogenic blood transfusions: clinical manifestations and mechanisms. Vox Sang 74 (Suppl 2): 315–319PubMedCrossRefGoogle Scholar
  7. 6.
    Blumberg N, Heal JM (1994) Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 118: 371–379Google Scholar
  8. 7.
    Bordin JO, Blajchman MA (1995) Immunosuppresive effects of allogeneic blood transfusions: implications for the patient with malignancy. Hematol Oncol Clin North Am 9: 205–218PubMedGoogle Scholar
  9. 8.
    Bureau of Labor Statistics. Labor Force Statistics from the Current Population Survey: Series LFS6&. Available at: http: // Accessed March 23, 2001Google Scholar
  10. 9.
    Case D, Bukowski R, Carey R et al (1993) Recombinant-human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85 (10): 801–806PubMedCrossRefGoogle Scholar
  11. 10.
    Cella D, Bron D (1999) The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 7 (4): 177–182PubMedCrossRefGoogle Scholar
  12. 11.
    Cerham JR (1997) New epidemiologic leads in the etiology of non-Hodgkin lymphoma in the elderly: the role of blood transfusion and diet. Biomed Pharmacother 51: 200–207CrossRefGoogle Scholar
  13. 12.
    Cremieux P, Barrett B, Anderson K et al (2000) Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 18 (14): 2755–2761PubMedGoogle Scholar
  14. 13.
    Cremieux P, Finkelstein SN, Berndt ER et al (1999) Cost-effectiveness, quality-adjusted life year and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anemia. Pharmacoeconomics 16 (5 pt 1): 459–472PubMedCrossRefGoogle Scholar
  15. 14.
    Cremieux P, Gubens M, Holland M, Slavin M (2000) Costs associated with anemia and cancer. ONE 1 (11): 1–4Google Scholar
  16. 15.
    DelMastro L, Venturini M et al (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15 (7): 2715–2721Google Scholar
  17. 16.
    Demetri G, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or, tumor type: results from a prospective community oncology study. J Clin Oncol 16 (10): 3412–3425PubMedGoogle Scholar
  18. 17.
    Engert A (2000) Recombinant human erthythropoietin as an alternative to blood transfusion in cancer-related anemia. Dis Manage Health Outcomes 8 (5): 259–272CrossRefGoogle Scholar
  19. 18.
    Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer therapy: a fresh look at an old problem. Semin Hematol 34 (Suppl 2): 20–26PubMedGoogle Scholar
  20. 19.
    Glaspy J, Bukowski R, Steinberg D et al (1997) The impact of therapy with epoetin alfa on clinical outcomes during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  21. 20.
    Gold MR, Siegel JE, Russel LB et al (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New YorkGoogle Scholar
  22. 21.
    Groopman JE (1998) Fatigue in cancer and HIV/AIDS. Oncology (Huntington) 12: 335–346, 351Google Scholar
  23. 22.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 (19): 1616–1634PubMedCrossRefGoogle Scholar
  24. 23.
    Henry D (1994) Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 8 (5): 961–973PubMedGoogle Scholar
  25. 24.
    Jilani S, Glaspy J (1998) Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol 25 (5): 571–576PubMedGoogle Scholar
  26. 25.
    Koeller JM (1998) Clinical guidelines for the treatment of cancer related anemia. Pharmacotherapy 18: 156–169PubMedGoogle Scholar
  27. 26.
    Kosary CL, Ries LAG, Miller BA et al (1995) SEER Cancer Statistics Review, 1973–1992: Tables and Graphs. Bethesda, MD, National Cancer Institute, NIH Pub. No. 96–2789Google Scholar
  28. 27.
    Michael M, Tannock IF (1998) Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ 158 (130): 1727–1734PubMedGoogle Scholar
  29. 28.
    Ortega A, Dranitsaris G, Piodziunas A (1998) What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 83 (12): 2588–2596PubMedCrossRefGoogle Scholar
  30. 29.
    Padilla GV, Grant MM, Ferrell BR, Presant CA (1996) Quality of life-cancer. In: Spilker B (ed) Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edn. Lippincott-Raven, Philadelphia, pp 301–308Google Scholar
  31. 30.
    Sheffield R, Sullivan S, Saltiel E et al (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15–22PubMedGoogle Scholar
  32. 31.
    Silberstein LE, Kruskall, MS, Stehling LC et al (1989) Strategies for the review of transfusion practices. JAMA 262: 1993–1997PubMedCrossRefGoogle Scholar
  33. 32.
    United States Census Bureau (1990) Census of Population and Housing. Available at: http.// &gr_name=DEC_I990_STFI_QTPI—Ul &_lang=en. Accessed March 23, 2001Google Scholar
  34. 33.
    Walsh D, Doona M, Molnar M, Lipnickey V (2000) Symptom control in advanced cancer: important drugs and routes of administration. Semin Oncol 27 (1): 69–83PubMedGoogle Scholar
  35. 34.
    Welch HG, Meehan KR, Goodnough LT (1992) Prudent strategies for elective red blood cell transfusion. Ann Intern Med 116: 393–402PubMedGoogle Scholar
  36. 35.
    Wheatly T, Veitch PS (1997) Effect of blood transfusion on postoperative immunocompetence [editorial]. Br J Anaesth 78: 489–492Google Scholar
  37. 36.
    Yellen SD, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy ( FACT) measurement system. J Pain Symptom Manage 13: 63–74Google Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  • Pierre-Y. Cremieux
    • 2
  • E. Dial
    • 1
  • M. Gustafson
    • 1
  • B. Sarokhan
    • 3
  • M. B. Slavin
    • 3
  1. 1.Analysis Group/EconomicsCambridgeUSA
  2. 2.Université du Québec à MontréalMontréalCanada
  3. 3.Ortho Biotech Products, LPRaritanUSA

Personalised recommendations